Enliven Therapeutics Reports $20.1 Million Net Loss in Q3 2025, Cash Reserves Increase to $477.6 Million

Enliven Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $20.1 million, a decrease from the $23.2 million loss recorded in the same period last year. For the nine months ending September 30, 2025, the company reported a net loss of $74.0 million, compared to a loss of $65.8 million for the same period in 2024. The reduction in quarterly losses is attributed to a decrease in research and development expenses, which fell to $18.2 million from $21.3 million year-over-year, primarily due to reduced costs associated with the ELVN-002 program as the company explores strategic alternatives for this product.

Total operating expenses for the third quarter of 2025 were $25.1 million, down from $27.1 million in the prior year. The decrease was driven by lower research and development costs, which were partially offset by an increase in general and administrative expenses, which rose to $6.9 million from $5.8 million, largely due to higher stock-based compensation. The company reported other income of $4.9 million, primarily from interest income, which increased due to a higher investment balance.

As of September 30, 2025, Enliven Therapeutics had cash, cash equivalents, and marketable securities totaling $477.6 million, a significant increase from $318.1 million at the end of 2024. This increase is largely attributed to a successful public offering completed in June 2025, which raised approximately $230 million. The company’s total liabilities decreased to $14.8 million from $15.9 million at the end of 2024, reflecting a reduction in accrued expenses.

Operationally, Enliven Therapeutics is focusing on advancing its lead product candidate, ELVN-001, while planning to discontinue further development of ELVN-002 beyond 2025. The company is also exploring geographic expansion for its manufacturing capabilities, particularly in Europe. As of the latest report, the company had 59.3 million shares outstanding, up from 48.9 million at the end of 2024, reflecting ongoing capital-raising efforts.

Looking ahead, Enliven Therapeutics anticipates continued operating losses as it invests in the development of its product candidates. The company expects its existing cash reserves will be sufficient to fund operations for at least the next 12 months. However, it acknowledges the need for substantial additional capital to support ongoing research and development activities, regulatory approvals, and potential commercialization efforts. The company remains vigilant regarding macroeconomic conditions and their potential impact on its operations and funding strategies.